Knowing the HER2 status of ER+/PR+ breast cancer is important to choose the right treatment strategy so patients get the best care. Proliferation rate is the percentage of cancer cells that are ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Subcellular mislocalization of checkpoint controllers is now surfacing as a mechanism of deregulating cell proliferation in cancer. Figure 1: Oncogene Her2/neu-initiated, Akt-mediated p21 Cip1 ...

The FDA has started a priority review of Boehringer Ingelheim's small-molecule HER2 inhibitor zongertinib as a treatment for a form of lung cancer, setting up a decision later this year and giving ...

The observational study measured how physicians changed treatment plans after seeing HER2DX results and how patients did on the new plans.